FONDAPARINUX Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Fondaparinux, and when can generic versions of Fondaparinux launch?
Fondaparinux is a drug marketed by Brightgene, Dr Reddys Labs Ltd, Eugia Pharma, Hangzhou Zhongmei, Hengrui Pharma, and Scinopharm Taiwan. and is included in six NDAs.
The generic ingredient in FONDAPARINUX is fondaparinux sodium. There are fourteen drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the fondaparinux sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Fondaparinux
A generic version of FONDAPARINUX was approved as fondaparinux sodium by DR REDDYS LABS LTD on July 11th, 2011.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for FONDAPARINUX?
- What are the global sales for FONDAPARINUX?
- What is Average Wholesale Price for FONDAPARINUX?
Summary for FONDAPARINUX
| US Patents: | 0 |
| Applicants: | 6 |
| NDAs: | 6 |
| Drug Prices: | Drug price information for FONDAPARINUX |
| DailyMed Link: | FONDAPARINUX at DailyMed |
US Patents and Regulatory Information for FONDAPARINUX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brightgene | FONDAPARINUX SODIUM | fondaparinux sodium | SOLUTION;SUBCUTANEOUS | 218312-001 | Dec 18, 2024 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Scinopharm Taiwan | FONDAPARINUX SODIUM | fondaparinux sodium | SOLUTION;SUBCUTANEOUS | 208615-001 | Nov 14, 2018 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Eugia Pharma | FONDAPARINUX SODIUM | fondaparinux sodium | SOLUTION;SUBCUTANEOUS | 206918-002 | Dec 26, 2017 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Dr Reddys Labs Ltd | FONDAPARINUX SODIUM | fondaparinux sodium | SOLUTION;SUBCUTANEOUS | 091316-003 | Jul 11, 2011 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
